Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Keymed Biosciences Co: Clinical Trials & FDA Approval Profile

Keymed Biosciences Co (Global / Institutional) sponsors 49 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 23 active protocols (11 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)104 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Keymed Biosciences Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)49
Active Pipeline (Recruiting Now)23 (11)
Completed vs Stopped Early17 / 0 (0.0%)
Median Closed Actual Enrollment104 participants
Physical Hospital Site Disclosure98.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Keymed Biosciences Co
Hospital Research SiteLocationShared Protocols
Peking University People's HospitalBeijing, Beijing Municipality12
Beijing Children's Hospital, Capital Medical UniversityBeijing4
West China Hospital of Sichuan UniversityChengdu, Sichuan4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Keymed Biosciences Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04805411Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)Phase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Keymed Biosciences Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI